JP2020537488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537488A5 JP2020537488A5 JP2020503935A JP2020503935A JP2020537488A5 JP 2020537488 A5 JP2020537488 A5 JP 2020537488A5 JP 2020503935 A JP2020503935 A JP 2020503935A JP 2020503935 A JP2020503935 A JP 2020503935A JP 2020537488 A5 JP2020537488 A5 JP 2020537488A5
- Authority
- JP
- Japan
- Prior art keywords
- toxoid
- seq
- oligopeptide
- less
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015636 Oligopeptides Human genes 0.000 claims description 50
- 108010038807 Oligopeptides Proteins 0.000 claims description 50
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 34
- 231100000617 superantigen Toxicity 0.000 claims description 34
- 230000002238 attenuated effect Effects 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 230000005745 host immune response Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102220614803 Calmodulin-3_Y92A_mutation Human genes 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 102200041344 rs1553190285 Human genes 0.000 claims description 4
- 230000001018 virulence Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102220556325 Acyl-CoA-binding domain-containing protein 6_D27A_mutation Human genes 0.000 claims description 2
- 102220556310 Acyl-CoA-binding domain-containing protein 6_Y89A_mutation Human genes 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102220520208 Neutrophil cytosol factor 4_Y94A_mutation Human genes 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010044250 Toxic shock syndrome staphylococcal Diseases 0.000 claims description 2
- 102220469725 Voltage-dependent L-type calcium channel subunit beta-2_I46A_mutation Human genes 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 102220285551 rs1194403044 Human genes 0.000 claims description 2
- 102220201545 rs886041401 Human genes 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 208000017756 staphylococcal toxic-shock syndrome Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 230000028993 immune response Effects 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101000606032 Pomacea maculata Perivitellin-2 31 kDa subunit Proteins 0.000 description 1
- 101000606027 Pomacea maculata Perivitellin-2 67 kDa subunit Proteins 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 108010090623 galactose binding protein Proteins 0.000 description 1
- 102000021529 galactose binding proteins Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537706P | 2017-07-27 | 2017-07-27 | |
| US62/537,706 | 2017-07-27 | ||
| PCT/US2018/043687 WO2019023341A1 (en) | 2017-07-27 | 2018-07-25 | IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537488A JP2020537488A (ja) | 2020-12-24 |
| JP2020537488A5 true JP2020537488A5 (enExample) | 2021-09-02 |
| JP7303791B2 JP7303791B2 (ja) | 2023-07-05 |
Family
ID=65041106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503935A Active JP7303791B2 (ja) | 2017-07-27 | 2018-07-25 | スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11260120B2 (enExample) |
| EP (1) | EP3658181A4 (enExample) |
| JP (1) | JP7303791B2 (enExample) |
| CN (1) | CN110996993B (enExample) |
| CA (1) | CA3069747A1 (enExample) |
| MX (1) | MX2020001046A (enExample) |
| WO (1) | WO2019023341A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116497003A (zh) * | 2023-06-29 | 2023-07-28 | 北京百普赛斯生物科技股份有限公司 | 一种从溶液中纯化目标蛋白的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593114B1 (en) | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| AU758019B2 (en) | 1998-07-10 | 2003-03-13 | U.S. Medical Research Institute Of Infectious Diseases | Anthrax vaccine |
| SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| DK2083016T3 (da) | 2001-11-26 | 2011-10-03 | U S Medical Res Inst Of Infectious Diseases | Bakterielle superantigenvacciner |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| WO2008154101A1 (en) | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| AU2012266880A1 (en) | 2011-03-16 | 2013-10-03 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| CA2857666C (en) | 2011-12-02 | 2020-08-11 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
| US9815872B2 (en) | 2013-06-19 | 2017-11-14 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
-
2018
- 2018-07-25 CN CN201880047111.4A patent/CN110996993B/zh active Active
- 2018-07-25 JP JP2020503935A patent/JP7303791B2/ja active Active
- 2018-07-25 US US16/633,664 patent/US11260120B2/en active Active
- 2018-07-25 EP EP18838475.4A patent/EP3658181A4/en active Pending
- 2018-07-25 MX MX2020001046A patent/MX2020001046A/es unknown
- 2018-07-25 WO PCT/US2018/043687 patent/WO2019023341A1/en not_active Ceased
- 2018-07-25 CA CA3069747A patent/CA3069747A1/en active Pending
-
2022
- 2022-02-25 US US17/680,897 patent/US11826412B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6594385B2 (ja) | 免疫原性組成物 | |
| ES2657588T3 (es) | Vacunas de bioconjugados de bacterias grampositivas capsulares | |
| US10174085B2 (en) | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof | |
| US9109036B2 (en) | Immunogenic composition comprising alpha-hemolysin oligopeptides | |
| JP2016522259A5 (enExample) | ||
| JP7072921B2 (ja) | Ａ群レンサ球菌ワクチン | |
| JP2014507142A5 (enExample) | ||
| TW201946650A (zh) | 針對腹內感染之疫苗 | |
| JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
| US9789176B2 (en) | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus | |
| CN113329766A (zh) | 艰难梭菌多组分疫苗 | |
| KR20100114620A (ko) | 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신 | |
| JP2020537488A5 (enExample) | ||
| CN102292104A (zh) | 用于诱导抗金黄色葡萄球菌的保护性免疫应答的多肽 | |
| US11826412B2 (en) | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids | |
| US20180141981A1 (en) | Immunogenic composition comprising engineered alpha-hemolysin oligopeptides | |
| US20240390470A1 (en) | Non-Toxin Antigens For Clostridioides Difficile Vaccine | |
| RU2521501C2 (ru) | Иммуногенная композиция для применения в вакцинации против стафилококков | |
| JP2013090574A (ja) | ペプチドワクチン | |
| Palmer et al. | Recombinant Protein D from Haemophilus influenzae Induces Mouse Bactericidal Antibodies Against Typeable and Non-Typeable Haemophilus influenzae, which Partially Protect Infant Rats Against Serotype b Bacteraemia | |
| TWI635869B (zh) | 生物型佐劑及含彼之動物疫苗組成物 | |
| Mosqueira et al. | Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori Hpa. A antigen increases antibody levels in mouse serum suggesting that For. A behaves as a putative adjuvant | |
| NZ614460B2 (en) | Vaccines and compositions against streptococcus pneumoniae | |
| NZ614460A (en) | Vaccines and compositions against streptococcus pneumoniae |